AGM postponed and the January-March Interim Report rescheduled

The Board of Directors of Genovis AB has decided to postpone the planned Annual General Meeting from April 28 until June 9, 2011. The reason for the delay is that the AGM cannot be held during an ongoing rights issue. In addition, the Board decided to reschedule the January-March Interim Report for April 18 because all financial information must be disclosed before completion of the rights issue.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 46 10 12 35 sarah.fredriksson@genovis.com

Genovis develops and designs smart nanoparticles for preclinical imaging and diagnostics and also develops and sells tools for modification of antibodies.Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission ( 46 (0)31 745 50 00) is the Company’s certified adviser.